Volume 16 Supplement 2

Update on therapeutic temperature management

Open Access

Rewarming: facts and myths from the systemic perspective

  • V Scaravilli1,
  • D Bonacina1 and
  • G Citerio2
Critical Care201216(Suppl 2):A25

https://doi.org/10.1186/cc11283

Published: 7 June 2012

Introduction

Rewarming is a delicate phase of therapeutic hypothermia (TH). Adverse consequences of rewarming on the whole body may seriously limit the protective effects of hypothermia, leading to secondary injury. Thus, understanding, predicting, and managing possible systemic side effects of rewarming is important for guaranteeing TH efficacy. The aim of this brief report is to describe rewarming effects from a systemic perspective.

Hemodynamics and imbalance in oxygen consumption and delivery

TH linearly decreases the metabolic rate of homeothermic organisms. During the cooling process, tissue oxygen consumption (VO2) slows by roughly 6%/°C reduction in body temperature [1, 2], obeying the van't Hoff-Arrhenius law, which states that the rate of a biochemical reaction is halved for each 10°C decrease in temperature. The reduction in brain metabolism is similar [3].

In contrast, during rewarming, the possible appearance of a mismatch between total body oxygen demand and oxygen delivery (DO2) [4] has been recognized since the pioneer works of Hegnauer and colleagues on dogs [5] and Bigelow on humans [6]. Bigelow has described this side effect of rewarming as rewarming shock: 'This syndrome of acute acidosis, or rewarming shock, was characterized by a progressive decline in blood pH [...] associated with respiratory inadequacy [...]. A fall in blood pressure and tachycardia were features in some cases'. In more recent studies, rewarming shock after moderate TH seems to be a more infrequent eventuality, probably because TH management has been completely changed by the advent of ICUs and a far less hypothermic regimen. The mismatch between oxygen supply and consumption during rewarming could depend on numerous factors, including metabolic rate, abnormalities in oxygen extraction, cardiac output (CO), circulating blood volume, regional blood flow, pH, blood viscosity, and a shift in the hemoglobin dissociation curve. The physiopathology of this side effect of rewarming is not known. Rewarming from hypothermia is such a complex and metabolism-pervasive process to alter all of the possible determinants of a VO2/DO2 mismatch. Of the possible determinants of VO2/DO2, cardiac dysfunction has been the most investigated. Cooling determines a proportional decrease in cardiac output [1], heart rate, and mean arterial blood pressure, with no change in stroke volume and increased peripheral vascular resistance. During the maintenance stage of TH, the decrease in metabolic rate is equal to or greater than the decrease in cardiac output, and alteration of oxygen delivery is not a matter of concern. Preliminary clinical studies [7] and a recent meta-analysis [8] have shown a decrease in myocardial ischemic injury. Many of the alterations in the cardiovascular system occurring during hypothermia completely reverse during rewarming. Therefore, the rewarming phase could lead to a permanent deterioration of myocardial function and cardiac output. The pathophysiological mechanism underlying cardiac dysfunction induced by hypothermia rewarming has been studied by Tveita's group, first in vitro using a rat left ventricular papillary muscle [9] and then in vivo [10] in an intact rat model. These studies showed how post-rewarming systolic left ventricular dysfunction can be related to decreased myofibrillar Ca2+ sensitivity due to increased troponin C phosphorylation.

In addition, Blair and colleagues [11] and Morray and Pavlin [12] documented an increase in total oxygen consumption to values above prehypothermic controls in a dog model of rewarming after deep hypothermia. The authors suggested many possible explanations for this event. First, heterogeneous blood flow distribution [13] during hypothermia may determine areas of oxygen debt, with decreased or absent perfusion, that become hypoxic and generate lactate. During rewarming, these areas are reperfused and lactate re-enters normal oxidative pathways, consuming oxygen in the process. Second, with a return to normothermia, free radical oxidation [14, 15] and inflammatory response to injury [16, 17] could resume, leading to nonrespiratory utilization of oxygen and an increase of VO2 over pre-injury control. Third, shivering can occur during rewarming as a response to deviations from the temperature set point. The shivering response to maintain a constant core temperature is a concerted reaction involving skeletal muscle contraction and peripheral vasoconstriction. When shivering occurs during rewarming, it is associated with increased VO2 [18, 19] and hemodynamic instability [20].

Cain and Bradley 21] and Schumacker and colleagues [22] have described abnormalities of peripheral oxygen extraction in dogs during hypothermia, even with adequate oxygen delivery. An alteration in the temperature transition of oxidative phosphorylation has been documented in an animal model. Leducq and colleagues presented evidence for an abnormal pattern of oxidative phosphorylation control that correlated with a transition in mitochondrial permeability and persisted after rewarming [23]. This phenomenon may cause alterations in oxygen utilization during and after rewarming.

Kondratiev and colleagues addressed the problem of oxygen supply in a rat model of deep hypothermia (15°C) and rewarming [24]. The experiment demonstrated a reduction in cardiac output and oxygen delivery after prolonged deep hypothermia (15°C for 5 hours) compared with less prolonged exposure. The rewarming-related rightward shift of the oxygen hemoglobin saturation curve, which facilitates oxygen dissociation at the tissue level, compensated for compromised peripheral oxygen transport, leading to a stable oxygen supply. Knowing the events causing VO2/DO2 mismatch during rewarming is important in this phase of TH for monitoring and assuring adequate cerebral and whole body oxygen delivery. Low oxygen delivery accounts for the development of secondary injury, which limits the safety and effectiveness of TH. With this perspective in mind, we can suggest various measures to limit VO2/DO2 mismatch during rewarming.

First, rewarming after TH should be done slowly and in a controlled manner [25]. Eshel, in a rat model of TH, showed how rapid rewarming from moderate hypothermia is associated with more acute hemodynamic alterations compared with slow rewarming [25]. Similar effects were described in humans [26] and pediatric patients [27] undergoing TH for hypoxic ischemic encephalopathy and deep intraoperative hypothermia (27°C), respectively, as well as in the work of Hanhela and colleagues [28] on adults undergoing cardiopulmonary bypass for cardiac surgery.

Second, controlling pain, sedation, and preventing shivering should limit oxygen consumption. Michenfelder and colleagues [29], Rodriguez and colleagues [30], and Zwischenberger and colleagues [31] demonstrated that the suppression of shivering by neuromuscular blockade is an effective method for diminishing VO2. More recently, Badjata and colleagues [32] proposed a simple shivering grading tool, the Bedside Shivering Assessment Scale (BSAS), developed by assessing the correlation of bedside shivering and systemic metabolic stress quantified by indirect calorimetry. Using clinical observation of muscle involvement, the BSAS provides an accurate representation of shivering-related oxygen consumption. Accurately defining shivering intensity assures the possibility of a stepwise treatment for shivering. We recommend initially managing shivering with nonsedating interventions, such as correcting hypomagnesemia, or a serotonin (5-TH) 1A partial agonist like buspirone or meperidine. Meperidine has been demonstrated to effectively reduce VO2 augmentation associated with postoperative shivering at a dosage that does not cause respiratory depression [33]. When these first line interventions fail, sedation with short-acting sedative agents and neuromuscular blockade can be used.

Third, oxygen content and transport should be optimized. Anemia and arterial desaturation must be avoided during rewarming. To date, no clinical trials have examined hemodynamic optimization in patients that have undergone TH, least of all during rewarming, and no evidence is currently available to indicate the best strategy for hemodynamic support in such a critical phase. We suggest a strict control of hemodynamics, with the aim of guaranteeing adequate oxygen delivery and avoiding VO2/DO2 mismatch, using at least continuous arterial pressure monitoring, volume balance and urine output surveillance, and frequent serum lactate measurements. In the case of hemodynamic instability, advanced monitoring capable of finer management could be useful. Thus, in this context, echocardiography and goal-directed hemodynamic optimization [34] may have a place. Treatment of systolic left ventricular impairment presents additional concerns. Pharmacological therapy with catecholamines presents substantial limitations [35, 36], as the decreased myofilament Ca2+ sensitivity during rewarming significantly diminishes β-adrenoceptor effects. In addition, catecholamines determine elevated myocardial oxygen consumption and arrhythmogenesis. A recent study by Rungatscher and colleagues [37] tested the efficacy of levosimendan in improving myocardial dysfunction after rewarming from deep hypothermia in a rat model. Levosimendan, as a Ca2+ sensitizer, demonstrated better inotropic and lusitropic effects than epinephrine.

Glycemic homeostasis

Animal models have shown that hypothermia induces alterations in blood glucose homeostasis via several mechanisms: reduced glucose utilization [38], decreased endogenous insulin secretion [3941], and increased resistance to exogenous insulin [42, 43]. In a recently published prospective observational study dealing with glycemic homeostasis during TH after cardiac arrest (CA), Cueni-Villoz and colleagues found a significantly higher mean blood glucose concentration, blood glucose variability, and insulin dose during TH compared with the normothermia that follows passive rewarming [44]. Because the doses of adrenergic agents did not change significantly between the two steps, the authors advocated lower endogenous insulin levels and the development of insulin resistance as an explanation for the findings. The improvement in glycemic control observed during normothermia, despite lower insulin infusion, suggests that progressive recovery towards normal glycemic homeostasis occurred during rewarming. The rate of hypoglycemic episodes correlated with poor neurological outcome and was similar during TH (8%) and normothermia (7.5%), but more frequently in patients who presented with higher blood glucose variability during TH. These data highlight the importance of progressive tapering of insulin doses to avoid hypoglycemia during passive rewarming from TH after CA, especially for patients who exhibited abrupt glucose shifts during TH.

The importance of glycemic control is further outlined in a recent work by Smith and colleagues. The alteration of blood glucose homeostasis is associated with increased ICU morbidity and poor outcome [45]. Passive rewarming from TH increases insulin sensitivity, but active rewarming from cardiopulmonary bypass decreases it. In both settings, rewarming is characterized by a dynamic insulin/glucose ratio; glucose should be checked frequently and insulin requirements promptly adapted to achieve optimal glycemic control.

Electrolytes

Mild hypothermia shifts potassium inside the cells and predisposes the patient to hypokalemia, as well as hypocalcemia, hypomagnesemia, and hypophosphatemia. During rewarming, rebound increases in these electrolytes (particularly potassium) may occur, especially if they were replaced excessively during the cooling period [46]. Hyperkalemia can be prevented by slow and controlled rewarming, allowing the kidney to excrete the excess potassium. In patients with severe oliguria or anuria, renal replacement therapy should be started before rewarming to avoid hyperkalemia.

Systemic inflammation

TH has been shown to suppress ischemia-induced cerebral and systemic inflammation after traumatic brain injury (TBI) in preclinical [4751] and clinical settings [16]. Following CA and reperfusion, TH is the only effective therapy for increasing survival and decreasing morbidity [52], probably by impairing harmful inflammatory reactions, which characterize systemic ischemia-reperfusion syndrome [53]. In a recent study, Bisschops and colleagues measured the kinetics of inflammatory mediators during TH and rewarming after CA [16]. Proinflammatory IL-6 increased during the TH phase, but values were surprisingly lower after rewarming. Anti-inflammatory IL-10 and IL-1RA did not significantly change over time. Complement and adhesion molecules, an index of endothelial activation, were elevated at admission, fell to low values during TH, and increased again after rewarming, confirming the hypothesis that inflammatory processes reactivate with the increase in temperature [17]. Interestingly, no significant differences were found between artery and jugular samples, confirming that the ischemia-reperfusion phenomenon is not confined to the brain, but affects the whole organism.

Fast rewarming rates have been shown to predict worse outcomes in animal models [49, 54, 55] due to the rapid reactivation of the inflammatory processes that were set-off by TH. Even if experimental evidence shows the advantages of controlled rewarming, additional clinical studies are needed to determine the optimal rewarming rate and strategy. Several drugs have also been tested recently in cell culture, tissue, and animal models to check their ability to mitigate the detrimental effects of rewarming. Data from Schmitt and colleagues suggest that pretreatment with methylprednisolone increases cerebral cell survival after deep hypothermia [50], but also suppresses important neuroprotective and regenerative processes induced by the proinflammatory cytokine IL-6. Diestel and colleagues focused on endothelial cells [56], which maintain systemic inflammation via cytokine production. Only combined pretreatment with methylprednisolone and tacrolimus inhibited IL-6 secretion. A specific p38 inhibitor was demonstrated to downregulate the unwanted release of IL-6 after cooling and rewarming most effectively. In a rat model of intestinal ischemia, gradual rewarming and administration of dexamethasone improved [48] survival and attenuated ALI after intestinal ischemia/reperfusion injury treated with TH in rats . Alva and colleagues [15] found that metabolic acidosis induced by rewarming was prevented by fructose 1,6-biphosphate (F1,6BP) administration in rats. F1,6BP also protected against oxidative stress induced after rewarming by decreasing lipid peroxidation in the plasma and potentiating antioxidant enzyme activities in erythrocytes. These results may be due to an increase in plasma nitric oxide and leukocytosis after the F1,6BP bolus. Other preclinical studies dealing with the anti-inflammatory safety and efficacy of these drugs are needed before a clinical study can start.

Infections

The most described infectious complication during TH is pneumonia. As most of the pneumonia diagnoses are made during rewarming or after achieving normothermia [57, 58], several authors have claimed that rewarming itself should be considered a high risk for infection. However, as the studies cited above adopted TH for 24 hours and achieved normothermia in the following 12 to 24 hours, the occurrence of pneumonia diagnosis during or after rewarming could also be due to latency from inoculation to the clinical manifestation of infection. Moreover, as hypothermia causes an impaired inflammatory response, clinical signs of infection leading to the diagnosis may be fully detectable only after reactivation of the immune system during or after rewarming. Whether more gradual controlled rewarming can reduce the frequency of pneumonia is unclear. In a small case series [59], even very slow controlled rewarming (0.1°C/hour) was associated with a high frequency of pulmonary infection, perhaps because slow rewarming prolongs the total duration of hypothermia.

Coagulation

Mild platelet dysfunction occurs at temperatures <35°C, and some inhibition of the coagulation cascade develops at temperatures <33°C. In TH after TBI [58] and stroke [57], the platelet count can also decrease, which persists during and after rewarming. In neonatal cold injury, death occurring during rewarming has been attributed to massive thrombosis from platelet hyperaggregation [60].

All of these data suggest that, in the clinical setting, attention must be paid to rewarming rates and attaining the target temperature to assure the optimal effects of hypothermia. The rewarming rate is an important variable; slower rewarming rates should be routinely employed to avoid systemic side effects.

Authors’ Affiliations

(1)
Department of Experimental Medicine, University of Milano-Bicocca, Ospedale San Gerardo
(2)
Neuroanesthesia and Neurointensive Care Unit, Department of Perioperative Medicine and Intensive Care, Ospedale San Gerardo

References

  1. Wong KC: Physiology and pharmacology of hypothermia. West J Med. 1983, 138: 227-232.PubMed CentralPubMedGoogle Scholar
  2. Bacher A, Illievich UM, Fitzgerald R, Ihra G, Spiss CK: Changes in oxygenation variables during progressive hypothermia in anesthetized patients. J Neurosurg Anesthesiol. 1997, 9: 205-210. 10.1097/00008506-199707000-00001.View ArticlePubMedGoogle Scholar
  3. Michenfelder JD, Theye RA: Hypothermia: effect on canine brain and whole-body metabolism. Anesthesiology. 1968, 29: 1107-1112. 10.1097/00000542-196811000-00005.View ArticlePubMedGoogle Scholar
  4. Lubarsky DA, Smith LR, Sladen RN, Mault JR, Reed RL: Defining the relationship of oxygen delivery and consumption: use of biologic system models. J Surg Res. 1995, 58: 503-508. 10.1006/jsre.1995.1079.View ArticlePubMedGoogle Scholar
  5. Hegnauer AH, Flynn J, D'Amato H: Cardiac physiology in dog during rewarming from deep hypothermia. Am J Physiol. 1951, 167: 69-75.PubMedGoogle Scholar
  6. Bigelow WC: Methods for inducing hypothermia and rewarming. Ann N Y Acad Sci. 1959, 80: 522-532.View ArticlePubMedGoogle Scholar
  7. Dixon SR, Whitbourn RJ, Dae MW, Grube E, Sherman W, Schaer GL, et al: Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol. 2002, 40: 1928-1934. 10.1016/S0735-1097(02)02567-6.View ArticlePubMedGoogle Scholar
  8. Mottillo S, Sharma K, Eisenberg MJ: Therapeutic hypothermia in acute myocardial infarction: a systematic review. Can J Cardiol. 2011, 27: 555-561. 10.1016/j.cjca.2010.12.027.View ArticlePubMedGoogle Scholar
  9. Han YS, Tveita T, Prakash YS, Sieck GC: Mechanisms underlying hypothermia-induced cardiac contractile dysfunction. Am J Physiol Heart Circ Physiol. 2010, 298: H890-H897. 10.1152/ajpheart.00805.2009.View ArticlePubMedGoogle Scholar
  10. Tveita T, Myklebust R, Ytrehus K: Changes in myocardial ultrastructure induced by cooling as well as rewarming. Res Exp Med (Berl). 1998, 197: 243-254. 10.1007/s004330050073.View ArticleGoogle Scholar
  11. Blair E, Montgomery AV, Swan H: Posthypothermic circulatory failure. I. Physiologic observations on the circulation. Circulation. 1956, 13: 909-915.View ArticlePubMedGoogle Scholar
  12. Morray JP, Pavlin EG: Oxygen delivery and consumption during hypothermia and rewarming in the dog. Anesthesiology. 1990, 72: 510-516. 10.1097/00000542-199003000-00020.View ArticlePubMedGoogle Scholar
  13. Steen PA, Milde JH, Michenfelder JD: The detrimental effects of prolonged hypothermia and rewarming in the dog. Anesthesiology. 1980, 52: 224-230. 10.1097/00000542-198003000-00007.View ArticlePubMedGoogle Scholar
  14. Talaei F, Bouma HR, Van der Graaf AC, Strijkstra AM, Schmidt M, Henning RH: Serotonin and dopamine protect from hypothermia/rewarming damage through the CBS/H2S pathway. PLoS One. 2011, 6: e22568-10.1371/journal.pone.0022568.PubMed CentralView ArticlePubMedGoogle Scholar
  15. Alva N, Carbonell T, Roig T, Bermudez J, Palomeque J: Fructose 1,6 biphosphate administration to rats prevents metabolic acidosis and oxidative stress induced by deep hypothermia and rewarming. Eur J Pharmacol. 2011, 659: 259-264. 10.1016/j.ejphar.2011.03.034.View ArticlePubMedGoogle Scholar
  16. Bisschops LL, Hoedemaekers CW, Mollnes TE, van der Hoeven JG: Rewarming after hypothermia after cardiac arrest shifts the inflammatory balance. Crit Care Med. 2012, 40: 1136-1142. 10.1097/CCM.0b013e3182377050.View ArticlePubMedGoogle Scholar
  17. Hildebrand F, van Griensven M, Giannoudis P, Luerig A, Harwood P, Harms O, et al: Effects of hypothermia and re-warming on the inflammatory response in a murine multiple hit model of trauma. Cytokine. 2005, 31: 382-393. 10.1016/j.cyto.2005.06.008.View ArticlePubMedGoogle Scholar
  18. Horvath SM, Spurr GB, Hutt BK, Hamilton LH: Metabolic cost of shivering. J Appl Physiol. 1956, 8: 595-602.PubMedGoogle Scholar
  19. Bay J, Nunn JF, Prys-Roberts C: Factors influencing arterial PO2 during recovery from anaesthesia. Br J Anaesth. 1968, 40: 398-407. 10.1093/bja/40.6.398.View ArticlePubMedGoogle Scholar
  20. Ralley FE, Wynands JE, Ramsay JG, Carli F, MacSullivan R: The effects of shivering on oxygen consumption and carbon dioxide production in patients rewarming from hypothermic cardiopulmonary bypass. Can J Anaesth. 1988, 35: 332-337. 10.1007/BF03010851.View ArticlePubMedGoogle Scholar
  21. Cain SM, Bradley WE: Critical O2 transport values at lowered body temperatures in rats. J Appl Physiol. 1983, 55: 1713-1717.PubMedGoogle Scholar
  22. Schumacker PT, Rowland J, Saltz S, Nelson DP, Wood LD: Effects of hyperthermia and hypothermia on oxygen extraction by tissues during hypovolemia. J Appl Physiol. 1987, 63: 1246-1252.PubMedGoogle Scholar
  23. Leducq N, Delmas-Beauvieux MC, Bourdel-Marchasson I, Dufour S, Gallis JL, Canioni P, et al: Mitochondrial permeability transition during hypothermic to normothermic reperfusion in rat liver demonstrated by the protective effect of cyclosporin A. Biochem J. 1998, 336 (Pt 2): 501-506.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Kondratiev TV, Flemming K, Myhre ES, Sovershaev MA, Tveita T: Is oxygen supply a limiting factor for survival during rewarming from profound hypothermia?. Am J Physiol Heart Circ Physiol. 2006, 291: H441-H450. 10.1152/ajpheart.01229.2005.View ArticlePubMedGoogle Scholar
  25. Polderman KH, Callaghan J: Equipment review: cooling catheters to induce therapeutic hypothermia?. Crit Care. 2006, 10: 234-10.1186/cc5023.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Thoresen M, Whitelaw A: Cardiovascular changes during mild therapeutic hypothermia and rewarming in infants with hypoxic-ischemic encephalopathy. Pediatrics. 2000, 106 (1 Pt 1): 92-99.View ArticlePubMedGoogle Scholar
  27. Saleh M, Barr TM: The impact of slow rewarming on inotropy, tissue metabolism, and 'after drop' of body temperature in pediatric patients. J Extra Corpor Technol. 2005, 37: 173-179.PubMedGoogle Scholar
  28. Hanhela R, Mustonen A, Korhonen I, Salomaki T: The effects of two rewarming strategies on heat balance and metabolism after coronary artery bypass surgery with moderate hypothermia. Acta Anaesthesiol Scand. 1999, 43: 979-988. 10.1034/j.1399-6576.1999.431003.x.View ArticlePubMedGoogle Scholar
  29. Michenfelder JD, Uihlein A, Daw EF, Theye RA: Moderate hypothermia in man: haemodynamic and metabolic effects. Br J Anaesth. 1965, 37: 738-745. 10.1093/bja/37.10.738.View ArticlePubMedGoogle Scholar
  30. Rodriguez JL, Weissman C, Damask MC, Askanazi J, Hyman AI, Kinney JM: Physiologic requirements during rewarming: suppression of the shivering response. Crit Care Med. 1983, 11: 490-497.PubMedGoogle Scholar
  31. Zwischenberger JB, Kirsh MM, Dechert RE, Arnold DK, Bartlett RH: Suppression of shivering decreases oxygen consumption and improves hemodynamic stability during postoperative rewarming. Ann Thorac Surg. 1987, 43: 428-431. 10.1016/S0003-4975(10)62823-8.View ArticlePubMedGoogle Scholar
  32. Badjatia N, Strongilis E, Gordon E, Prescutti M, Fernandez L, Fernandez A, et al: Metabolic impact of shivering during therapeutic temperature modulation: the Bedside Shivering Assessment Scale. Stroke. 2008, 39: 3242-3247. 10.1161/STROKEAHA.108.523654.View ArticlePubMedGoogle Scholar
  33. Macintyre PE, Pavlin EG, Dwersteg JF: Effect of meperidine on oxygen consumption, carbon dioxide production, and respiratory gas exchange in postanesthesia shivering. Anesth Analg. 1987, 66: 751-755.View ArticlePubMedGoogle Scholar
  34. Jones AE, Shapiro NI, Kilgannon JH, Trzeciak S: Goal-directed hemodynamic optimization in the post-cardiac arrest syndrome: a systematic review. Resuscitation. 2008, 77: 26-29. 10.1016/j.resuscitation.2007.10.021.View ArticlePubMedGoogle Scholar
  35. Tveita T, Sieck GC: The physiologic responses to epinephrine during cooling and after rewarming in vivo. Crit Care. 2011, 15: R225-10.1186/cc10465.PubMed CentralView ArticlePubMedGoogle Scholar
  36. Weiss SJ, Muniz A, Ernst AA, Lippton HL: The physiological response to norepinephrine during hypothermia and rewarming. Resuscitation. 1998, 39: 189-195. 10.1016/S0300-9572(98)00137-3.View ArticlePubMedGoogle Scholar
  37. Rungatscher A, Linardi D, Tessari M, Menon T, Luciani GB, Mazzucco A, et al: Levosimendan is superior to epinephrine in improving myocardial function after cardiopulmonary bypass with deep hypothermic circulatory arrest in rats. J Thorac Cardiovasc Surg. 2012, 143: 209-214. 10.1016/j.jtcvs.2011.09.020.View ArticlePubMedGoogle Scholar
  38. Escolar JC, Hoo-Paris R, Castex C, Sutter BC: Effect of low temperatures on glucose-induced insulin secretion and glucose metabolism in isolated pancreatic islets of the rat. J Endocrinol. 1990, 125: 45-51. 10.1677/joe.0.1250045.View ArticlePubMedGoogle Scholar
  39. Blackard WG, Nelson NC, Labat JA: Insulin secretion in hypothermic dogs. Am J Physiol. 1967, 212: 1185-1187.PubMedGoogle Scholar
  40. Escolar JC, Hoo-Paris R, Castex C, Sutter BC: Effect of low temperatures on glucose-induced insulin secretion and ionic fluxes in rat pancreatic islets. J Endocrinol. 1987, 115: 225-231. 10.1677/joe.0.1150225.View ArticlePubMedGoogle Scholar
  41. Sasaki Y, Takahashi H, Aso H, Ohneda A, Weekes TE: Effects of cold exposure on insulin and glucagon secretion in sheep. Endocrinology. 1982, 111: 2070-2076. 10.1210/endo-111-6-2070.View ArticlePubMedGoogle Scholar
  42. Helman A, Gilbert M, Pfister-Lemaire N, Reach G, Assan R: Glucagon and insulin secretion and their biological activities in hypothermic rats. Endocrinology. 1984, 115: 1722-1728. 10.1210/endo-115-5-1722.View ArticlePubMedGoogle Scholar
  43. Torlinska T, Perz M, Madry E, Hryniewiecki T, Nowak KW, Mackowiak P: Effect of hypothermia on insulin-receptor interaction in different rat tissues. Physiol Res. 2002, 51: 261-266.PubMedGoogle Scholar
  44. Cueni-Villoz N, Devigili A, Delodder F, Cianferoni S, Feihl F, Rossetti AO, et al: Increased blood glucose variability during therapeutic hypothermia and outcome after cardiac arrest. Crit Care Med. 2011, 39: 2225-2231. 10.1097/CCM.0b013e31822572c9.View ArticlePubMedGoogle Scholar
  45. Smith FG, Sheehy AM, Vincent JL, Coursin DB: Critical illness-induced dysglycaemia: diabetes and beyond. Crit Care. 2010, 14: 327-10.1186/cc9266.PubMed CentralView ArticlePubMedGoogle Scholar
  46. Polderman KH, Peerdeman SM, Girbes AR: Hypophosphatemia and hypomagnesemia induced by cooling in patients with severe head injury. J Neurosurg. 2001, 94: 697-705. 10.3171/jns.2001.94.5.0697.View ArticlePubMedGoogle Scholar
  47. Alam HB, Rhee P, Honma K, Chen H, Ayuste EC, Lin T, et al: Does the rate of rewarming from profound hypothermic arrest influence the outcome in a swine model of lethal hemorrhage?. J Trauma. 2006, 60: 134-146. 10.1097/01.ta.0000198469.95292.ec.View ArticlePubMedGoogle Scholar
  48. Kim K, Jo YH, Rhee JE, Kim TY, Lee JH, Kwon WY, et al: Effect of speed of rewarming and administration of anti-inflammatory or anti-oxidant agents on acute lung injury in an intestinal ischemia model treated with therapeutic hypothermia. Resuscitation. 2010, 81: 100-105. 10.1016/j.resuscitation.2009.09.020.View ArticlePubMedGoogle Scholar
  49. Gordan ML, Kellermann K, Blobner M, Nollert G, Kochs EF, Jungwirth B: Fast rewarming after deep hypothermic circulatory arrest in rats impairs histologic outcome and increases NFkappaB expression in the brain. Perfusion. 2010, 25: 349-354. 10.1177/0267659110377946.View ArticlePubMedGoogle Scholar
  50. Schmitt KR, Kern C, Berger F, Ullrich O, Hendrix S, Abdul-Khaliq H: Methylprednisolone attenuates hypothermia- and rewarming-induced cytotoxicity and IL-6 release in isolated primary astrocytes, neurons and BV-2 microglia cells. Neurosci Lett. 2006, 404: 309-314. 10.1016/j.neulet.2006.05.064.View ArticlePubMedGoogle Scholar
  51. Vaagenes P, Gundersen Y, Opstad PK: Rapid rewarming after mild hypothermia accentuates the inflammatory response after acute volume controlled haemorrhage in spontaneously breathing rats. Resuscitation. 2003, 58: 103-112. 10.1016/S0300-9572(03)00102-3.View ArticlePubMedGoogle Scholar
  52. Bernard SA, Buist M: Induced hypothermia in critical care medicine: a review. Crit Care Med. 2003, 31: 2041-2051. 10.1097/01.CCM.0000069731.18472.61.View ArticlePubMedGoogle Scholar
  53. Scumpia PO, Sarcia PJ, Kelly KM, DeMarco VG, Skimming JW: Hypothermia induces anti-inflammatory cytokines and inhibits nitric oxide and myeloperoxidase-mediated damage in the hearts of endotoxemic rats. Chest. 2004, 125: 1483-1491. 10.1378/chest.125.4.1483.View ArticlePubMedGoogle Scholar
  54. Maxwell WL, Watson A, Queen R, Conway B, Russell D, Neilson M, et al: Slow, medium, or fast re-warming following post-traumatic hypothermia therapy? An ultrastructural perspective. J Neurotrauma. 2005, 22: 873-884. 10.1089/neu.2005.22.873.View ArticlePubMedGoogle Scholar
  55. Berger C, Xia F, Kohrmann M, Schwab S: Hypothermia in acute stroke - slow versus fast rewarming an experimental study in rats. Exp Neurol. 2007, 204: 131-137. 10.1016/j.expneurol.2006.10.002.View ArticlePubMedGoogle Scholar
  56. Diestel A, Roessler J, Pohl-Schickinger A, Koster A, Drescher C, Berger F, et al: Specific p38 inhibition in stimulated endothelial cells: a possible new anti-inflammatory strategy after hypothermia and rewarming. Vascul Pharmacol. 2009, 51: 246-252. 10.1016/j.vph.2009.06.006.View ArticlePubMedGoogle Scholar
  57. Schwab S, Schwarz S, Spranger M, Keller E, Bertram M, Hacke W: Moderate hypothermia in the treatment of patients with severe middle cerebral artery infarction. Stroke. 1998, 29: 2461-2466. 10.1161/01.STR.29.12.2461.View ArticlePubMedGoogle Scholar
  58. Metz C, Holzschuh M, Bein T, Woertgen C, Frey A, Frey I, et al: Moderate hypothermia in patients with severe head injury: cerebral and extracerebral effects. J Neurosurg. 1996, 85: 533-541. 10.3171/jns.1996.85.4.0533.View ArticlePubMedGoogle Scholar
  59. Steiner T, Friede T, Aschoff A, Schellinger PD, Schwab S, Hacke W: Effect and feasibility of controlled rewarming after moderate hypothermia in stroke patients with malignant infarction of the middle cerebral artery. Stroke. 2001, 32: 2833-2835. 10.1161/hs1201.99511.View ArticlePubMedGoogle Scholar
  60. Diephuis JC, Balt J, van Dijk D, Moons KG, Knape JT: Effect of rewarming speed during hypothermic cardiopulmonary bypass on cerebral pressure-flow relation. Acta Anaesthesiol Scand. 2002, 46: 283-288. 10.1034/j.1399-6576.2002.t01-1-460310.x.View ArticlePubMedGoogle Scholar

Copyright

© Scaravilli et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.